Glucose Tolerance, Triglyceride Levels in Prediabetes Improve With Sitagliptin

Share this content:
Researchers urge further study on sitagliptin's effect on slowing the progression of prediabetes.
Researchers urge further study on sitagliptin's effect on slowing the progression of prediabetes.

This article is part of Endocrinology Advisor's coverage of the American Diabetes Association's 77th Scientific Sessions (ADA 2017), taking place in San Diego, CA. Our staff will report on medical research and technological advances in diabetes and diabetes education, conducted by experts in the field. Check back regularly for more news from ADA 2017.


Treatment with sitagliptin improved several lipid parameters for men who were overweight and had prediabetes, according to research presented at the American Diabetes Association (ADA) 77th Scientific Sessions, June 9-13, in San Diego, California.

Because the effect of sitagliptin on prediabetes is not well known, researchers from Spain and The Netherlands conducted a randomized double-blind placebo-controlled study to evaluate the effect of the dipeptidyl peptidase-4 inhibitor on glucose tolerance, plasma lipid levels, energy expenditure, brown and white fat, and skeletal muscle metabolism in men with prediabetes who were overweight.

 

The mean age of participants was 45.9±6.2 years and body mass index was 28.6±2.7 kg/m2. Participants were randomly assigned to receive either sitagliptin (100 mg/d; n=15) or placebo (n=15) for 12 weeks.

Sitagliptin improved glucose excursion (area under the curve [AUC], –14%; P <.001) after oral glucose tolerance testing and lowered triglyceride levels (AUC, –29%; P =.054) without affecting body composition, energy expenditure, substrate preference, or skeletal muscle mRNA gene expression.

Sitagliptin did not affect F-fluorodeoxyglucose uptake by brown fat, but it did increase the uptake in subcutaneous white adipose tissue (AUC, +45%; P <.05).

"Studies on the effect of sitagliptin on preventing or delaying the progression of prediabetes and dyslipidemia in individuals at risk for developing type 2 diabetes are warranted," the researchers wrote.


Visit Endocrinology Advisor's conference section for continuous coverage from ADA 2017


Reference

Nahon KJ, Doornink F, Straat ME, et al. Sitagliptin improves glucose tolerance and serum triglyceride levels in overweight, prediabetic Caucasian men. Abstract 153-LB. Presented at: American Diabetes Association 77th Scientific Sessions. June 9-13, 2017; San Diego, CA. 

You must be a registered member of Endocrinology Advisor to post a comment.